Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Reversible non-covalent BTK inhibitor

Pirtobrutinib (Specialist drug)

Brand names: Jaypirca

Pirtobrutinib is an oral, non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor used in certain B-cell malignancies such as mantle cell lymphoma.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It reversibly binds BTK, including at the cysteine-481 site, inhibiting B-cell receptor signalling and retaining activity in some tumours resistant to covalent BTK inhibitors.

Prescribing in practice

  • Serious infections, including opportunistic infections, can occur due to immunosuppression, so patients should be monitored and infections treated promptly.
  • Haemorrhage, atrial fibrillation/flutter, and cytopenias are recognised class-related risks requiring monitoring.
  • Second primary malignancies, including skin cancers, have been reported, so sun protection and skin surveillance are advised.

Monitoring

Monitor full blood count, cardiac rhythm, and for signs of infection or bleeding during treatment.

Counselling the patient

  • Report fever or infection symptoms, unusual bruising or bleeding, and any palpitations promptly.
  • Use sun protection and report new or changing skin lesions.
  • Effective contraception is recommended during and after treatment.

Evidence & guidelines

The BRUIN study supported approval of pirtobrutinib in B-cell malignancies, including disease previously treated with covalent BTK inhibitors.

Reference: NICE TA987; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways